Literature DB >> 7177566

Nanophthalmos with uveal effusion: clinical and embryologic considerations.

E A Ryan, J Zwaan, L T Chylack.   

Abstract

Three brothers were found to have nanophthalmos as evidenced by marked hyperopia, decreased global axial length, and shallow anterior chambers. The thickness of the lens, measured with A-scan ultrasound biometry in two cases, was much greater than normal. Choroidal thickening with shallow retinal detachments without breaks was found in those patients. Fluorescein angioscopy demonstrated leaks beneath the serous retinal detachments in one. The spontaneous presence of choroidal effusions and retinal detachments in nanophthalmic patients has been reported only rarely. The present findings emphasize that careful examination of the posterior segment should be done prior to anterior segment surgery in these patients to alert the surgeon to the possibility of serious intra- and post-operative choroidal effusions and retinal detachments. An attempt is made to explain some of the clinical findings in nanophthalmos by extrapolating from results obtained on experimental animals. It is postulated that the increased lens size in nanophthalmos may be due to the abnormal accumulation of a factor influencing lens fiber differentiation. The overall small size of the eye may be the result of the formation of a smaller than usual optic vesicle anlage.

Entities:  

Mesh:

Year:  1982        PMID: 7177566     DOI: 10.1016/s0161-6420(82)34686-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  The nanophthalmic macula.

Authors:  J C Serrano; P R Hodgkins; D S Taylor; G A Gole; A Kriss
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

Review 2.  Classification of microphthalmos and coloboma.

Authors:  M Warburg
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

3.  Uveal Effusion Syndrome: Clinical Characteristics, Outcome of Surgical Treatment, and Histopathological Examination of the Sclera.

Authors:  Nan Zhou; Lihong Yang; Xiaolin Xu; Wenbin Wei
Journal:  Front Med (Lausanne)       Date:  2022-06-09

4.  High-hyperopia database, part I: clinical characterisation including morphometric (biometric) differentiation of posterior microphthalmos from nanophthalmos.

Authors:  N Relhan; S Jalali; N Pehre; H L Rao; U Manusani; L Bodduluri
Journal:  Eye (Lond)       Date:  2015-10-23       Impact factor: 3.775

5.  Developmental basis of nanophthalmos: MFRP Is required for both prenatal ocular growth and postnatal emmetropization.

Authors:  Olof H Sundin; Sharola Dharmaraj; Imran A Bhutto; Takuya Hasegawa; D Scott McLeod; Carol A Merges; Eduardo D Silval; Irene H Maumenee; Gerard A Lutty
Journal:  Ophthalmic Genet       Date:  2008-03       Impact factor: 1.803

6.  Angle closure in younger patients.

Authors:  Brian M Chang; Jeffrey M Liebmann; Robert Ritch
Journal:  Trans Am Ophthalmol Soc       Date:  2002

7.  A clinical and molecular genetic study of a rare dominantly inherited syndrome (MRCS) comprising of microcornea, rod-cone dystrophy, cataract, and posterior staphyloma.

Authors:  M A Reddy; P J Francis; V Berry; K Bradshaw; R J Patel; E R Maher; R Kumar; S S Bhattacharya; A T Moore
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

8.  Autosomal dominant simple microphthalmos.

Authors:  E M Vingolo; K Steindl; R Forte; L Zompatori; A Iannaccone; A Sciarra; G Del Porto; M R Pannarale
Journal:  J Med Genet       Date:  1994-09       Impact factor: 6.318

9.  Exudative retinal detachment following cataract surgery in Hallermann-Streiff syndrome.

Authors:  Sachiko Nishina; Yumi Suzuki; Noriyuki Azuma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-12       Impact factor: 3.117

10.  Compound heterozygosity for a novel and a recurrent MFRP gene mutation in a family with the nanophthalmos-retinitis pigmentosa complex.

Authors:  Juan Carlos Zenteno; Beatriz Buentello-Volante; Miguel A Quiroz-González; Miguel A Quiroz-Reyes
Journal:  Mol Vis       Date:  2009-09-05       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.